| | |
Summary: Radiotherapy and Dosimetry of 64
Cu-TETA-Tyr3
-Octreotate in a
Somatostatin Receptor-positive, Tumor-bearing Rat Model1
Jason S. Lewis, Michael R. Lewis,
P. Duffy Cutler, Ananth Srinivasan,
Michelle A. Schmidt, Sally W. Schwarz,
Margaret M. Morris, J. Philip Miller, and
Carolyn J. Anderson2
Mallinckrodt Institute of Radiology, Washington University School of
Medicine, St. Louis, Missouri 63110 [J. S. L., M. R. L., P. D. C.,
S. W. S., M. M. M., C. J. A.]; Division of Biostatistics, Washington
University School of Medicine, St. Louis, Missouri 63110 [J. P. M.];
and Mallinckrodt, Inc., Hazelwood, Missouri 63042 [A. S., M. A. S.]
ABSTRACT
64
Cu [T1/2 12.8 h; 0.655 MeV (19%);
0.573 MeV (40%)] has shown promise as a radioisotope for
targeted radiotherapy. It has been demonstrated previously
that the somatostatin analogue 64
|
